Markus Muschen, MD, PhD

Title(s)Professor, Laboratory Medicine
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Institute of Genetics, University of Cologne, Cologne, GermanyMD-PhD2003Department of Immunology
    University Medical Center Cologne, Cologne, GermanyClinical training2001Department of Haematology-Oncology
    University Medical Center Düsseldorf, GermanyPhysician-in-training2000Department of Medicine
    University of Dusseldorf, GermanyM.D.2000University Medical Center Düsseldorf
    University of Paris V, René Descartes, FranceMedical student1997Institut Pasteur
    University of Nantes, Nantes, FranceMedical student1995INSERM Unité 437, Transplantation Immunology
    Collapse Awards and Honors
    Howard Hughes Medical Institute2016HHMI Faculty Scholar Award
    National Cancer Institute2016NCI Outstanding Investigator Award
    Wellcome Trust2013Wellcome Trust Senior Investigator Award
    The Institute of Cancer Research, London, UK2012Haddow Professorship
    Leukemia and Lymphoma Society2010Scholar Award
    German Association of Hematology and Oncology2006Leukemia Research Award
    German Association for Immunology2004Fritz-Melchers Award
    University of Cologne2003Habilitation Thesis Award
    State of North-Rhine Westphalia2002Stem Cell Research Award
    German Science Foundation (DFG)2001Emmy-Noether Young Investigator Award
    Heinrich-Heine-Universitat Dusseldorf1999Doctoral Thesis Award

    Collapse Overview 
    Collapse Overview

    R01CA137060-A1 Müschen (PI) 04/01/2008 - 12/31/2012
    “Pre-B cell receptor signaling in acute lymphoblastic leukemia”. The central goal of this project is to clarify the role of pre-B cell receptor signaling in acute lymphoblastic leukemia.

    R01CA139032 Müschen (PI) 04/01/2008 - 12/31/2012
    “AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia”. The central goal is (1) to identify the regulatory mechanisms that lead to aberrant expression of AID and (2) to identify the consequences of aberrant AID-activity in leukemia cells.

    1R01CA157644 Müschen (PI) 04/01/2011-03/31/2016
    ‘Infectious origins of childhood leukemia’. The central goal of this proposal is to experimentally test the ‘delayed infections hypothesis’ in the etiology of childhood ALL and to delineate mechanisms of genetic vulnerability of human pre-B cells in the context of infection.

    R21CA152497 Müschen (PI) 06/01/2010 - 05/31/2012
    “Mechanism of BCL6-dependent stem cell maintenance in B cell lineage leukemia”. The central goals of this proposal are (1) to clarify the role of BCL6 in leukemia-initiation of Ph+ ALL and (2) To determine the frequency and phenotype of BCL6-dependent leukemia stem cells.

    TR2-01816 Müschen (PI) 10/01/2010-09/30/2013
    California Institute for Regenerative Medicine (CIRM)
    Early Translation Award. Development of a BCL6 small molecule inhibitor for targeted eradication of leukemia stem cells. The main goals of this project are (1) computer aided drug-design of BCL6 lateral groove inhibitors, (2) PK/PD assays and SAR studies of identified lead compound series and (3) pre-clinical validation.

    AACR 138564 Müschen (PI) 12/01/2009 - 11/30/2012
    AACR Stand Up To Cancer Innovation Award
    Stand Up To Cancer Innovation Award: Role of BCL6 in leukemia stem cell self-renewal. The main goal of this project is to study the role of BCL6 in the maintenance of leukemia-initiating cells in ALL.

    LLS 1497-11 Müschen (PI) 10/01/2010-09/30/2015
    The Leukemia and Lymphoma Society Scholar Award
    Leukemia and Lymphoma Society Scholar Award, will cover salary expenses related to NIH grant R01CA137060 ‘Pre-B cell receptor signaling in acute lymphoblastic leukemia’.

    LLS 6132-09 Müschen (PI) 10/01/2008-09/30/2012
    The Leukemia and Lymphoma Society
    Translational Research Grant ‘Targeting AID in BCR-ABL1-driven leukemia’. The main goal of this project is to study the role of AID in aberrant somatic hypermutation as a cause of genetic instability.

    LLS 6097-10 Müschen (PI) 07/01/2009-06/30/2013
    The Leukemia and Lymphoma Society
    Translational Research Grant ‘BCL6 in oncogene-induced senescence’. The main goal of this project is to study the role of BCL6 in oncogene-induced senescence in MYC-driven B cell lymphoma.

    LLS 7005-11 Müschen (Project-PI) 10/01/2010-09/30/2015
    Leukemia and Lymphoma Society SCOR
    Project 2: Dual targeting of tyrosine kinase and feedback signaling in leukemia. Goals are identification of novel oncogenic tyrosine kinases and characterization of feedback mechanisms in response to tyrosine kinase inhibition. Brian J Druker, Portland, OR is the PI of the SCOR.

    LLS 7005-11 Müschen (Project-PI) 10/01/2010-09/30/2015
    Leukemia and Lymphoma Society SCOR
    Core E: (1) Generate and make xenografted samples available to SCOR projects, (2) Generate a centralized multidimensional database which links flow cytometry data, cytogenetics, gene expression, SNP chip analysis and clinical information. Brian J Druker, Portland, OR is the PI of the SCOR.

    Collapse Research 
    Collapse Research Activities and Funding
    CD25-mediated feedback control of BCR-signaling and its oncogenic mimics
    NIH/NCI R01CA213138Jun 1, 2017 - May 31, 2022
    Role: Principal Investigator
    Metabolic basis of B cell lineage leukemia relapse
    NIH/NCI R35CA197628Apr 1, 2016 - Mar 31, 2023
    Role: Principal Investigator
    Negative feedback signaling in tyrosine kinase-driven leukemia
    NIH/NCI R01CA172558Jul 1, 2013 - Apr 30, 2018
    Role: Principal Investigator
    Targeting BCL6 in tyrosine kinase-driven leukemia
    NIH/NCI R01CA169458May 15, 2013 - Apr 30, 2018
    Role: Principal Investigator
    Targeted activation of autoimmune checkpoints in B cell malignancies
    NIH/NCI R01CA157644Jun 1, 2011 - Dec 31, 2021
    Role: Principal Investigator
    Mechanism of BCL6-dependent stem cell maintenance in B cell lineage leukemia
    NIH/NCI R21CA152497Jul 1, 2010 - Jun 30, 2012
    Role: Principal Investigator
    AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia
    NIH/NCI R01CA139032Mar 18, 2009 - Jan 31, 2015
    Role: Principal Investigator
    NIH/NCI R01CA137060Dec 1, 2008 - Jan 31, 2019
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Global Health
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Deng R, Hurtz C, Song Q, Yue C, Xiao G, Yu H, Wu X, Muschen M, Forman S, Martin PJ, Zeng D. Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun. 2017 10 17; 8(1):978. PMID: 29042531.
      View in: PubMed
    2. Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest. 2017 Jun 01; 127(6):2392-2406. PMID: 28481221.
      View in: PubMed
    3. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. PMID: 27479034.
      View in: PubMed
    4. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. PMID: 27070704.
      View in: PubMed
    5. Sun H, Lin DC, Guo X, Kharabi Masouleh B, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP. Inhibition of IRE1a-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. Oncotarget. 2016 Apr 05; 7(14):18736-49. PMID: 26934650; PMCID: PMC4951325.
    6. Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med. 2016 Apr; 22(4):379-87. PMID: 26974310.
      View in: PubMed
    7. Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016 04 28; 127(17):2131-43. PMID: 26864341.
      View in: PubMed
    8. Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE, Burger JA. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia. 2016 06; 30(6):1246-54. PMID: 26847027.
      View in: PubMed
    9. Cao Q, Gearhart MD, Gery S, Shojaee S, Yang H, Sun H, Lin DC, Bai JW, Mead M, Zhao Z, Chen Q, Chien WW, Alkan S, Alpermann T, Haferlach T, Müschen M, Bardwell VJ, Koeffler HP. BCOR regulates myeloid cell proliferation and differentiation. Leukemia. 2016 05; 30(5):1155-65. PMID: 26847029.
      View in: PubMed
    10. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep. 2015 Dec 29; 13(12):2715-27. PMID: 26711339; PMCID: PMC4700051.
    11. Song C, Pan X, Ge Z, Gowda C, Ding Y, Li H, Li Z, Yochum G, Muschen M, Li Q, Payne KJ, Dovat S. Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia. Leukemia. 2016 06; 30(6):1436-40. PMID: 26639180.
      View in: PubMed
    12. Greaves M, Müschen M. Infection and the Perils of B-cell Activation. Cancer Discov. 2015 Dec; 5(12):1244-6. PMID: 26637659; PMCID: PMC4758198.
    13. Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood. 2015 Nov 05; 126(19):2202-12. PMID: 26324703.
      View in: PubMed
    14. Song C, Gowda C, Pan X, Ding Y, Tong Y, Tan BH, Wang H, Muthusami S, Ge Z, Sachdev M, Amin SG, Desai D, Gowda K, Gowda R, Robertson GP, Schjerven H, Muschen M, Payne KJ, Dovat S. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. Blood. 2015 Oct 08; 126(15):1813-22. PMID: 26219304.
      View in: PubMed
    15. Swaminathan S, Müschen M. Infectious origins of childhood leukemia. Oncotarget. 2015 Jul 10; 6(19):16798-9. PMID: 26196452.
      View in: PubMed
    16. Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM, Müschen M. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):114-28. PMID: 26073130.
      View in: PubMed
    17. Montamat-Sicotte D, Litzler LC, Abreu C, Safavi S, Zahn A, Orthwein A, Müschen M, Oppezzo P, Muñoz DP, Di Noia JM. HSP90 inhibitors decrease AID levels and activity in mice and in human cells. Eur J Immunol. 2015 Aug; 45(8):2365-76. PMID: 25912253.
      View in: PubMed
    18. Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke N, Mooster J, Geng H, Schwarz K, Kogan SC, Casellas R, Schatz DG, Lieber MR, Greaves MF, Müschen M. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol. 2015 Jul; 16(7):766-774. PMID: 25985233.
      View in: PubMed
    19. Müschen M. Ph+ ALL: drawing strength from a benign past. Blood. 2015 May 07; 125(19):2879-80. PMID: 25953975.
      View in: PubMed
    20. Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW. YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. J Hematol Oncol. 2015 Apr 22; 8:39. PMID: 25895498.
      View in: PubMed
    21. Müschen M. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood. 2015 Jun 11; 125(24):3688-93. PMID: 25878119.
      View in: PubMed
    22. Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 2015 May 21; 521(7552):357-61. PMID: 25799995.
      View in: PubMed
    23. Buchner M, Park E, Geng H, Klemm L, Flach J, Passegué E, Schjerven H, Melnick A, Paietta E, Kopanja D, Raychaudhuri P, Müschen M. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. Nat Commun. 2015 Mar 10; 6:6471. PMID: 25753524.
      View in: PubMed
    24. Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Bijl JJ, Ye BH, Ansel KM, Paietta E, Melnick A, Hunger SP, Kurre P, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Chang BH, Müschen M. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 2015 Mar 09; 27(3):409-25. PMID: 25759025.
      View in: PubMed
    25. Lu Z, Lieber MR, Tsai AG, Pardo CE, Müschen M, Kladde MP, Hsieh CL. Human lymphoid translocation fragile zones are hypomethylated and have accessible chromatin. Mol Cell Biol. 2015 Apr; 35(7):1209-22. PMID: 25624348.
      View in: PubMed
    26. Buchner M, Swaminathan S, Chen Z, Müschen M. Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia. Immunol Rev. 2015 Jan; 263(1):192-209. PMID: 25510278.
      View in: PubMed
    27. Swaminathan S, Müschen M. Follicular lymphoma: too many reminders for a memory B cell. J Clin Invest. 2014 Dec; 124(12):5095-8. PMID: 25384212.
      View in: PubMed
    28. Fontanari Krause LM, Japp AS, Krause A, Mooster J, Chopra M, Müschen M, Bohlander SK. Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL. Sci Rep. 2014 Oct 09; 4:6565. PMID: 25298122.
      View in: PubMed
    29. Buchner M, Müschen M. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr Opin Hematol. 2014 Jul; 21(4):341-9. PMID: 24811161.
      View in: PubMed
    30. Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, Huang C, Swaminathan S, Sun H, Paietta E, Melnick AM, Koeffler P, Müschen M. Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2014 May 27; 111(21):E2219-28. PMID: 24821775.
      View in: PubMed
    31. Tsai CT, Yang PM, Chern TR, Chuang SH, Lin JH, Klemm L, Müschen M, Chen CC. AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine. Oncotarget. 2014 Jan 15; 5(1):211-23. PMID: 24457556.
      View in: PubMed
    32. Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, Alexandrov LB, Van Loo P, Cooke SL, Marshall J, Martincorena I, Hinton J, Gundem G, van Delft FW, Nik-Zainal S, Jones DR, Ramakrishna M, Titley I, Stebbings L, Leroy C, Menzies A, Gamble J, Robinson B, Mudie L, Raine K, O'Meara S, Teague JW, Butler AP, Cazzaniga G, Biondi A, Zuna J, Kempski H, Muschen M, Ford AM, Stratton MR, Greaves M, Campbell PJ. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014 Feb; 46(2):116-25. PMID: 24413735.
      View in: PubMed
    33. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Müschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar; 4(3):362-75. PMID: 24346116.
      View in: PubMed
    34. Swaminathan S, Duy C, Müschen M. BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint. Trends Immunol. 2014 Mar; 35(3):131-7. PMID: 24332591; PMCID: PMC3943645.
    35. Mangum DS, Downie J, Mason CC, Jahromi MS, Joshi D, Rodic V, Müschen M, Meeker N, Trede N, Frazer JK, Zhou Y, Cheng C, Jeha S, Pui CH, Willman CL, Harvey RC, Hunger SP, Yang JJ, Barnette P, Mullighan CG, Miles RR, Schiffman JD. VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia. Leukemia. 2014 Jan; 28(1):216-20. PMID: 23881307; PMCID: PMC4043450.
    36. Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, Nowak D, Thoennissen GB, Rand V, Graeber TG, Koeffler HP, Carroll WL, Willman CL, Hall AG, Igarashi K, Melnick A, Müschen M. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med. 2013 Aug; 19(8):1014-22. PMID: 23852341; PMCID: PMC3954721.
    37. Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood. 2013 Aug 15; 122(7):1293-304. PMID: 23836560; PMCID: PMC3744994.
    38. Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, Park E, Naing K, Klemm L, Swaminathan S, Conway EM, Pelus LM, Crispino J, Mullighan CG, McMillan M, Müschen M, Kahn M, Kim YM. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene. 2014 Apr 24; 33(17):2169-78. PMID: 23728349; PMCID: PMC3994178.
    39. Parameswaran R, Lim M, Arutyunyan A, Abdel-Azim H, Hurtz C, Lau K, Müschen M, Yu RK, von Itzstein M, Heisterkamp N, Groffen J. O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia. J Exp Med. 2013 Apr 08; 210(4):805-19. PMID: 23478187; PMCID: PMC3620349.
    40. Hsieh YT, Gang EJ, Geng H, Park E, Huantes S, Chudziak D, Dauber K, Schaefer P, Scharman C, Shimada H, Shojaee S, Klemm L, Parameswaran R, Loh M, Kang ES, Koo HH, Hofmann WK, Andrade J, Crooks GM, Willman CL, Müschen M, Papayannopoulou T, Heisterkamp N, Bönig H, Kim YM. Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood. 2013 Mar 07; 121(10):1814-8. PMID: 23319569; PMCID: PMC3591800.
    41. Cui X, Lu Z, Kurosawa A, Klemm L, Bagshaw AT, Tsai AG, Gemmell N, Müschen M, Adachi N, Hsieh CL, Lieber MR. Both CpG methylation and activation-induced deaminase are required for the fragility of the human bcl-2 major breakpoint region: implications for the timing of the breaks in the t(14;18) translocation. Mol Cell Biol. 2013 Mar; 33(5):947-57. PMID: 23263985; PMCID: PMC3623081.
    42. Ramezani-Rad P, Geng H, Hurtz C, Chan LN, Chen Z, Jumaa H, Melnick A, Paietta E, Carroll WL, Willman CL, Lefebvre V, Müschen M. SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood. 2013 Jan 03; 121(1):148-55. PMID: 23152540; PMCID: PMC3538327.
    43. Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 2012 Nov 13; 22(5):656-67. PMID: 23153538; PMCID: PMC3500515.
    44. Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, Luger SM, Lazarus H, Tallman MS, Rowe JM, Litzow MR, Guzman ML, Allis CD, Roeder RG, Müschen M, Paietta E, Elemento O, Melnick AM. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov. 2012 Nov; 2(11):1004-23. PMID: 23107779; PMCID: PMC3516186.
    45. Iacobucci I, Iraci N, Messina M, Lonetti A, Chiaretti S, Valli E, Ferrari A, Papayannidis C, Paoloni F, Vitale A, Storlazzi CT, Ottaviani E, Guadagnuolo V, Durante S, Vignetti M, Soverini S, Pane F, Foà R, Baccarani M, Müschen M, Perini G, Martinelli G. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLoS One. 2012; 7(7):e40934. PMID: 22848414; PMCID: PMC3405023.
    46. Ridges S, Heaton WL, Joshi D, Choi H, Eiring A, Batchelor L, Choudhry P, Manos EJ, Sofla H, Sanati A, Welborn S, Agarwal A, Spangrude GJ, Miles RR, Cox JE, Frazer JK, Deininger M, Balan K, Sigman M, Müschen M, Perova T, Johnson R, Montpellier B, Guidos CJ, Jones DA, Trede NS. Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood. 2012 Jun 14; 119(24):5621-31. PMID: 22490804; PMCID: PMC3382926.
    47. Jiang XX, Nguyen Q, Chou Y, Wang T, Nandakumar V, Yates P, Jones L, Wang L, Won H, Lee HR, Jung JU, Müschen M, Huang XF, Chen SY. Control of B cell development by the histone H2A deubiquitinase MYSM1. Immunity. 2011 Dec 23; 35(6):883-96. PMID: 22169041; PMCID: PMC4098839.
    48. Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, Shah NP, Melnick AM, Müschen M. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011 Oct 24; 208(11):2163-74. PMID: 21911423; PMCID: PMC3201200.
    49. Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, Ye BH, Melnick A, Müschen M. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood. 2011 Oct 13; 118(15):4174-8. PMID: 21856866; PMCID: PMC3204735.
    50. Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim YM. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood. 2011 Aug 25; 118(8):2191-9. PMID: 21715311; PMCID: PMC3162353.
    51. Kwak LW, Goldenberg DM, Benz EJ, Yi Q, Müschen M, Wang D. American Journal of Blood Research: Editorial Board (2011) e-Century Publishing Corporation. Am J Blood Res. 2011; 1(1):106-9. PMID: 22432071; PMCID: PMC3301414.
    52. Kwak LW, Goldenberg DM, Benz EJ, Yi Q, Muschen M, Wang D. Launching of american journal of blood research. Am J Blood Res. 2011; 1(1):i. PMID: 22432072; PMCID: PMC3301420.
    53. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, Yu JJ, Heisterkamp N, Graeber TG, Wu H, Ye BH, Melnick A, Müschen M. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 2011 May 19; 473(7347):384-8. PMID: 21593872; PMCID: PMC3597744.
    54. Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res. 2011 May 15; 17(10):3219-32. PMID: 21474579; PMCID: PMC3096723.
    55. Rubbi L, Titz B, Brown L, Galvan E, Komisopoulou E, Chen SS, Low T, Tahmasian M, Skaggs B, Müschen M, Pellegrini M, Graeber TG. Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. Sci Signal. 2011 Mar 29; 4(166):ra18. PMID: 21447799; PMCID: PMC4057100.
    56. Thai M, Ting PY, McLaughlin J, Cheng D, Müschen M, Witte ON, Colicelli J. ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1. Leukemia. 2011 Feb; 25(2):290-300. PMID: 21102429; PMCID: PMC3049868.
    57. Gruber TA, Chang MS, Sposto R, Müschen M. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia. Cancer Res. 2010 Oct 01; 70(19):7411-20. PMID: 20876806; PMCID: PMC2948648.
    58. Fang C, Wang Y, Vu NT, Lin WY, Hsieh YT, Rubbi L, Phelps ME, Müschen M, Kim YM, Chatziioannou AF, Tseng HR, Graeber TG. Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples. Cancer Res. 2010 Nov 01; 70(21):8299-308. PMID: 20837665; PMCID: PMC3989903.
    59. Yun JP, Behan JW, Heisterkamp N, Butturini A, Klemm L, Ji L, Groffen J, Müschen M, Mittelman SD. Diet-induced obesity accelerates acute lymphoblastic leukemia progression in two murine models. Cancer Prev Res (Phila). 2010 Oct; 3(10):1259-64. PMID: 20823291; PMCID: PMC2955776.
    60. Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, Schuh W, Jäck HM, Hurtz C, Ramezani-Rad P, Herzog S, Jumaa H, Koeffler HP, de Alborán IM, Melnick AM, Ye BH, Müschen M. BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med. 2010 Jun 07; 207(6):1209-21. PMID: 20498019; PMCID: PMC2882829.
    61. Parameswaran R, Müschen M, Kim YM, Groffen J, Heisterkamp N. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res. 2010 Jun 01; 70(11):4346-56. PMID: 20460528; PMCID: PMC2880197.
    62. Müschen M. Genetic relicts from the origin of ALL. Blood. 2010 Apr 29; 115(17):3424-5. PMID: 20430963.
      View in: PubMed
    63. Wang XM, Greiner TC, Bibikova M, Pike BL, Siegmund KD, Sinha UK, Müschen M, Jaeger EB, Weisenburger DD, Chan WC, Shibata D, Fan JB, Hacia JG. Identification and functional relevance of de novo DNA methylation in cancerous B-cell populations. J Cell Biochem. 2010 Mar 01; 109(4):818-27. PMID: 20069569; PMCID: PMC3122883.
    64. Fei F, Stoddart S, Müschen M, Kim YM, Groffen J, Heisterkamp N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia. 2010 Apr; 24(4):813-20. PMID: 20111071; PMCID: PMC3038787.
    65. Nahar R, Müschen M. Pre-B cell receptor signaling in acute lymphoblastic leukemia. Cell Cycle. 2009 Dec; 8(23):3874-7. PMID: 19901533; PMCID: PMC4047560.
    66. Nowak D, Ogawa S, Müschen M, Kato M, Kawamata N, Meixel A, Nowak V, Kim HS, Kang S, Paquette R, Chang MS, Thoennissen NH, Thoenissen NH, Mossner M, Hofmann WK, Kohlmann A, Weiss T, Haferlach T, Haferlach C, Koeffler HP. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood. 2010 Feb 04; 115(5):1049-53. PMID: 19965645; PMCID: PMC2817631.
    67. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, Henke N, Li Z, Hoffmann TK, Kim YM, Hofmann WK, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber MR, Casellas R, Müschen M. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell. 2009 Sep 08; 16(3):232-45. PMID: 19732723.
      View in: PubMed
    68. Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, Park E, Schuh W, Gruber T, Herzog S, Kim YM, Hofmann WK, Li A, Storlazzi CT, Jäck HM, Groffen J, Martinelli G, Heisterkamp N, Jumaa H, Müschen M. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med. 2009 Aug 03; 206(8):1739-53. PMID: 19620627; PMCID: PMC2722172.
    69. Tsai AG, Lu H, Raghavan SC, Muschen M, Hsieh CL, Lieber MR. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell. 2008 Dec 12; 135(6):1130-42. PMID: 19070581; PMCID: PMC2642632.
    70. Iacobucci I, Lonetti A, Cilloni D, Messa F, Ferrari A, Zuntini R, Ferrari S, Ottaviani E, Arruga F, Paolini S, Papayannidis C, Piccaluga PP, Soverini S, Saglio G, Pane F, Baruzzi A, Vignetti M, Berton G, Vitale A, Chiaretti S, Müschen M, Foà R, Baccarani M, Martinelli G. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. Haematologica. 2008 Dec; 93(12):1814-21. PMID: 18838475.
      View in: PubMed
    71. Müschen M. Highlight: self-renewal signaling in stem cells. Biol Chem. 2008 Jul; 389(7):787. PMID: 18681824.
      View in: PubMed
    72. Melchior K, Weiss J, Zaehres H, Kim YM, Lutzko C, Roosta N, Hescheler J, Müschen M. The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cells. Biol Chem. 2008 Jul; 389(7):897-903. PMID: 18681827.
      View in: PubMed
    73. Kaur P, Feldhahn N, Zhang B, Trageser D, Müschen M, Pertz V, Groffen J, Heisterkamp N. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer. 2007 Oct 25; 6:67. PMID: 17958915; PMCID: PMC2169263.
    74. Feldhahn N, Henke N, Melchior K, Duy C, Soh BN, Klein F, von Levetzow G, Giebel B, Li A, Hofmann WK, Jumaa H, Müschen M. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J Exp Med. 2007 May 14; 204(5):1157-66. PMID: 17485517; PMCID: PMC2118573.
    75. Meixlsperger S, Köhler F, Wossning T, Reppel M, Müschen M, Jumaa H. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity. 2007 Mar; 26(3):323-33. PMID: 17331747.
      View in: PubMed
    76. Klapper W, Szczepanowski M, Heidorn K, Müschen M, Liedtke S, Sotnikova A, Andersen NS, Greeve J, Parwaresch R. Immunoglobulin class-switch recombination occurs in mantle cell lymphomas. J Pathol. 2006 Jun; 209(2):250-7. PMID: 16508921.
      View in: PubMed
    77. Sprangers M, Feldhahn N, Liedtke S, Jumaa H, Siebert R, Müschen M. SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells. Oncogene. 2006 Aug 24; 25(37):5180-6. PMID: 16636677.
      View in: PubMed
    78. Sprangers M, Feldhahn N, Herzog S, Hansmann ML, Reppel M, Hescheler J, Jumaa H, Siebert R, Müschen M. The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells. Oncogene. 2006 Aug 17; 25(36):5056-62. PMID: 16568084.
      View in: PubMed
    79. Klein F, Feldhahn N, Herzog S, Sprangers M, Mooster JL, Jumaa H, Müschen M. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene. 2006 Feb 16; 25(7):1118-24. PMID: 16205638.
      View in: PubMed
    80. Feldhahn N, Río P, Soh BN, Liedtke S, Sprangers M, Klein F, Wernet P, Jumaa H, Hofmann WK, Hanenberg H, Rowley JD, Müschen M. Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proc Natl Acad Sci U S A. 2005 Sep 13; 102(37):13266-71. PMID: 16141323; PMCID: PMC1201599.
    81. Soh BN, Klein F, Feldhahn N, Müschen M. B-lymphoid or myeloid lineage identity of cell lines derived from chronic myeloid leukemia blast crisis. Cancer Genet Cytogenet. 2005 Sep; 161(2):187-8. PMID: 16102593.
      View in: PubMed
    82. Feldhahn N, Klein F, Mooster JL, Hadweh P, Sprangers M, Wartenberg M, Bekhite MM, Hofmann WK, Herzog S, Jumaa H, Rowley JD, Müschen M. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J Exp Med. 2005 Jun 06; 201(11):1837-52. PMID: 15939795.
      View in: PubMed
    83. Klein F, Feldhahn N, Mooster JL, Sprangers M, Hofmann WK, Wernet P, Wartenberg M, Müschen M. Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. J Immunol. 2005 Jan 01; 174(1):367-75. PMID: 15611260.
      View in: PubMed
    84. Su YW, Herzog S, Lotz M, Feldhahn N, Müschen M, Jumaa H. The molecular requirements for LAT-mediated differentiation and the role of LAT in limiting pre-B cell expansion. Eur J Immunol. 2004 Dec; 34(12):3614-22. PMID: 15549729.
      View in: PubMed
    85. Klein F, Feldhahn N, Müschen M. Interference of BCR-ABL1 kinase activity with antigen receptor signaling in B cell precursor leukemia cells. Cell Cycle. 2004 Jul; 3(7):858-60. PMID: 15254401.
      View in: PubMed
    86. Kögler G, Sensken S, Airey JA, Trapp T, Müschen M, Feldhahn N, Liedtke S, Sorg RV, Fischer J, Rosenbaum C, Greschat S, Knipper A, Bender J, Degistirici O, Gao J, Caplan AI, Colletti EJ, Almeida-Porada G, Müller HW, Zanjani E, Wernet P. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med. 2004 Jul 19; 200(2):123-35. PMID: 15263023; PMCID: PMC2212008.
    87. Klein F, Feldhahn N, Harder L, Wang H, Wartenberg M, Hofmann WK, Wernet P, Siebert R, Müschen M. The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells. J Exp Med. 2004 Mar 01; 199(5):673-85. PMID: 14993251; PMCID: PMC2213306.
    88. Schuster VH, Müschen M. Epstein-Barr virus and the B cell: a secret romance. Trends Microbiol. 2003 Jun; 11(6):243-5. PMID: 12823936.
      View in: PubMed
    89. Klein F, Feldhahn N, Lee S, Wang H, Ciuffi F, von Elstermann M, Toribio ML, Sauer H, Wartenberg M, Barath VS, Krönke M, Wernet P, Rowley JD, Müschen M. T lymphoid differentiation in human bone marrow. Proc Natl Acad Sci U S A. 2003 May 27; 100(11):6747-52. PMID: 12738882; PMCID: PMC164518.
    90. Wartenberg M, Ling FC, Müschen M, Klein F, Acker H, Gassmann M, Petrat K, Pütz V, Hescheler J, Sauer H. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 2003 Mar; 17(3):503-5. PMID: 12514119.
      View in: PubMed
    91. Müschen M, Lee S, Zhou G, Feldhahn N, Barath VS, Chen J, Moers C, Krönke M, Rowley JD, Wang SM. Molecular portraits of B cell lineage commitment. Proc Natl Acad Sci U S A. 2002 Jul 23; 99(15):10014-9. PMID: 12119411; PMCID: PMC126616.
    92. Müschen M, Rajewsky K, Krönke M, Küppers R. The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol. 2002 Feb; 23(2):75-80. PMID: 11929130.
      View in: PubMed
    93. Müschen M, Re D, Betz B, Moers C, Wolf J, Niederacher D, Diehl V, Beckmann MW. Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene. Int J Cancer. 2001 Apr 15; 92(2):309-10. PMID: 11291062.
      View in: PubMed
    94. Müschen M, Küppers R, Spieker T, Bräuninger A, Rajewsky K, Hansmann ML. Molecular single-cell analysis of Hodgkin- and Reed-Sternberg cells harboring unmutated immunoglobulin variable region genes. Lab Invest. 2001 Mar; 81(3):289-95. PMID: 11310822.
      View in: PubMed
    95. Re D, Müschen M, Ahmadi T, Wickenhauser C, Staratschek-Jox A, Holtick U, Diehl V, Wolf J. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res. 2001 Mar 01; 61(5):2080-4. PMID: 11280769.
      View in: PubMed
    96. Küppers R, Bräuninger A, Müschen M, Distler V, Hansmann ML, Rajewsky K. Evidence that Hodgkin and Reed-Sternberg cells in Hodgkin disease do not represent cell fusions. Blood. 2001 Feb 01; 97(3):818-21. PMID: 11157505.
      View in: PubMed
    97. Müschen M, Re D, Jungnickel B, Diehl V, Rajewsky K, Küppers R. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J Exp Med. 2000 Dec 18; 192(12):1833-40. PMID: 11120779; PMCID: PMC2213498.
    98. Müschen M, Re D, Bräuninger A, Wolf J, Hansmann ML, Diehl V, Küppers R, Rajewsky K. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res. 2000 Oct 15; 60(20):5640-3. PMID: 11059754.
      View in: PubMed
    99. Müschen M, Beckmann MW. CD95 ligand expression as a criterion of malignant transformation in breast cancer. J Pathol. 2000 Aug; 191(4):468-70. PMID: 10918226.
      View in: PubMed
    100. Müschen M, Rajewsky K, Bräuninger A, Baur AS, Oudejans JJ, Roers A, Hansmann ML, Küppers R. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med. 2000 Jan 17; 191(2):387-94. PMID: 10637283; PMCID: PMC2195757.
    101. Müschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med (Berl). 2000; 78(6):312-25. PMID: 11001528.
      View in: PubMed
    102. Müschen M, Moers C, Warskulat U, Even J, Niederacher D, Beckmann MW. CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology. 2000 Jan; 99(1):69-77. PMID: 10651943; PMCID: PMC2327134.
    103. Müschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien R, Beckmann MW, Häussinger D. CD95 ligand expression in dedifferentiated breast cancer. J Pathol. 1999 Nov; 189(3):378-86. PMID: 10547600.
      View in: PubMed
    104. Müschen M, Warskulat U, Perniok A, Even J, Moers C, Kismet B, Temizkan N, Simon D, Schneider M, Häussinger D. Involvement of soluble CD95 in Churg-Strauss syndrome. Am J Pathol. 1999 Sep; 155(3):915-25. PMID: 10487849; PMCID: PMC1866905.
    105. Müschen M, Warskulat U, Peters-Regehr T, Bode JG, Kubitz R, Häussinger D. Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation. Gastroenterology. 1999 Mar; 116(3):666-77. PMID: 10029626.
      View in: PubMed
    106. Moers C, Warskulat U, Müschen M, Even J, Niederacher D, Josien R, Koldovsky U, Beckmann MW, Häussinger D. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin. Int J Cancer. 1999 Feb 09; 80(4):564-72. PMID: 9935158.
      View in: PubMed
    107. Josien R, Douillard P, Guillot C, Müschen M, Anegon I, Chetritt J, Menoret S, Vignes C, Soulillou JP, Cuturi MC. A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance. J Clin Invest. 1998 Dec 01; 102(11):1920-6. PMID: 9835616; PMCID: PMC509143.
    108. Müschen M, Warskulat U, Häussinger D, Moers C, Simon D, Even J. Deranged CD95 system in a case of Churg-Strauss vasculitis. Gastroenterology. 1998 Jun; 114(6):1351-2. PMID: 9618660.
      View in: PubMed
    109. Müschen M, Warskulat U, Douillard P, Gilbert E, Häussinger D. Regulation of CD95 (APO-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells. Hepatology. 1998 Jan; 27(1):200-8. PMID: 9425938.
      View in: PubMed